Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 17
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
BioHarvest Sciences Inc
BHST
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.38
-0.13
-8.31%
al cierre: Nov 16, 4:00 PM EST
$1.38
N/A
After hour: 4:11 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el jue nov 12th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 8:00 a. m., hace 5 días
Haz clic para ver el webcast
BioHarvest Sciences Financials
BioHarvest Sciences (BHST) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Conference call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $37.000M-$40.000M to $32.000M-$33.500M vs $37.461M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $37.000 million-$40.000 million to $32.000 million-$33.500 million vs $37.461 million estimate.
Benzinga Newsdesk
PRO
BioHarvest Sciences Inc. - Common Stock Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $7.867M Miss $9.371M Estimate
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 7.14 percent decrease over losses of
Benzinga Newsdesk
PRO
Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
Benzinga Newsdesk
PRO
BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M
BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA
Benzinga Newsdesk
PRO
BioHarvest Sciences Inc. - Common Stock Q2 EPS $(0.17) Misses $(0.12) Estimate, Sales $8.837M Miss $9.537M Estimate
Benzinga Newsdesk
PRO
BioHarvest Sciences Affirms FY2026 Sales Guidance of $42.000M-$48.000M vs $44.721M Est
BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million to $42.000 million-$48.000 million vs $44.721 million estimate.
Benzinga Newsdesk